Prof. Jørgen Vestbo (University of Manchester, United Kingdom) pointed out that industry has been claiming that smokers cannot or will not quit smoking. Yet, most smokers actually do want to quit and a high proportion dislikes being nicotine dependent [1]. Most smokers today already smoke less cigarettes daily and are more motivated than before to quit.
It has also been stated that alternative nicotine delivery products are highly effective as a smoking cessation aid, but evidence for this claim is lacking. On the contrary, a review of 38 studies concluded that the odds of quitting cigarettes were even 28% lower in those who used e-cigarettes compared with those who did not use e-cigarettes [2]. No matter whether smokers were motivated to quit or not, the e-cigarettes did not help them in the trials evaluated in the review (see Figure). The value of alternative nicotine delivery products as a tool for smoking cessation was also evaluated in a recent randomised controlled trial including 886 smokers [3].
In this trial, after one year, the abstinence rate of smokers was 18% on e-cigarettes and 9.9% on nicotine replacement products (P<0.001). However, 80% of quitters and 31% of smokers in the e-cigarette arm were still on e-cigarettes. In the nicotine replacement arm the numbers were 9% and 4%, respectively [3]. “Even if the e-cigarette users had a higher abstinence rate than nicotine replacement products in this trial, the difference is that you do not get addicted to nicotine replacement,” commented Prof. Vestbo.
Practice study confirms that e-cigarettes mainly lead to dual use
Another argument that has been proven false is that smokers will replace conventional cigarettes with alternative nicotine delivery products. In contrast, many e-cigarette users continue to smoke and there seems to be no significant reduction in their consumption of conventional cigarettes [2].
Figure: E-cigarettes have no benefit in smoking cessation [2]
This was also shown in a Swedish survey presented during the ERS 2019 congress [4]. “E-cigarettes have been around for 10 years now. Unfortunately, they also seem to appeal to nonsmokers, especially teenagers,” said Prof. Linnéa Hedman (Umeå University, Sweden). Her study aimed to find predictors for e-cigarette use and whether the use of e-cigarettes can really change smoking habits.
In 2006, Prof. Hedman sent a postal questionnaire to a random sample of adults aged 20 to 69 years. Data was collected on smoking habits, respiratory symptoms, sex, and occupation. Another questionnaire was sent 10 years later to the same people (now aged 30–79 years). This time the questionnaire also included a question on e-cigarette use. Of the original cohort, 81% returned the questionnaire. Data from 8,424 participants could be analysed in the study [4].
According to the follow-up questionnaire, 0.9% of participants used e-cigarettes; most of them were former smokers. Factors associated with e-cigarette use were young age (20–29 years) and current smoker. The latter had a more than 34-fold elevated risk to use e-cigarettes compared with non-smokers. At follow-up, 225 patients had quit smoking, but only 1 of them used e-cigarettes to do so. Of the e-cigarette users, 82% were persistent smokers. Among this group, 69% of smokers had not changed their daily number of cigarettes, 11% had increased it, and 20% decreased it.
“This study is only confirming again that e-cigarettes are no smoking cessation device, and that smokers are boosting their nicotine intake by e-cigarettes,” concluded chairman Prof. Elif Dağlı (University of Istanbul, Turkey).
- Vestbö J. Oral presentation 5476, ERS 2019, 29 Sept-2 Oct, Madrid, Spain.
- Kalkhoran S, Glantz SA. Lancet Respir Med 2016;4(2):116-28.
- Hajek P, et al. NEJM 2019:380:629-637.
- Hedman L. Oral presentation OA3313, ERS 2019, 29 Sept-2 Oct, Madrid, Spain.
Posted on
Previous Article
« Dual bronchodilation improves ventilation dynamics in COPD patients Next Article
Taxi drivers exposed to highest levels of black carbon pollution »
« Dual bronchodilation improves ventilation dynamics in COPD patients Next Article
Taxi drivers exposed to highest levels of black carbon pollution »
Table of Contents: ERS 2019
Featured articles
Letter from the Editor
Interview with ERS president Prof. Tobias Welte
Holistic View on Asthma
Holistic view on asthma
COPD Management
COPD patients derive clinical benefit from β-blockers
COPD patients harbouring Pseudomonas Aeruginosa face high risk of hospitalisation
One blood eosinophil count is sufficient to guide ICS therapy
Female COPD patients frequently suffer from anxiety and depression
Dual bronchodilation improves ventilation dynamics in COPD patients
Vaping
Vaping impairs innate immune response of the airway
Alternative nicotine delivery products: no help in smoking cessation
Air Pollution
Pregnant women and their offspring: a high-risk group for air pollution
Taxi drivers exposed to highest levels of black carbon pollution
Infectious Respiratory Disease: the Role of Vaccines
Vaccines show multiple positive effects with respect to respiratory health
Pneumococcal vaccines: an effective way to reduce COPD hospitalisations
Interstitial Lung Disease
Antifibrotic therapy slows disease progression in ILD
Reduction of FVC decline in systemic sclerosis-associated ILD
Registry confirms nintedanib efficacy under real-life conditions
Best of the Posters
Fever during immunotherapy for NSCLC associated with shorter PFS
Smart shirt as a device to measure tidal volumes in real-life setting
Exercise with virtual reality beneficial for COPD patients
NSCLC: A new way to evaluate hilar and mediastinal lymph nodes
COPD patients do not benefit from azithromycin therapy longer than a year
Novel Developments in Infectious Disease
Long-term azithromycin decreases exacerbations in primary ciliary dyskinesia
Predicting community-acquired pneumonia outcomes by microRNA testing
Pulmonary Vascular Disease
Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
Related Articles
September 10, 2020
Intensive hypertension treatment lowers risk of orthostatic hypotension
November 30, 2021
The scope of remote healthcare in hypertension and hyperlipidaemia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com